BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, Moisi JC, Adetifa IM, Karani A, Akech DO, Otiende M, Bwanaali T, Wafula J, Mataza C, Mumbo E, Tabu C, Knoll MD, Bauni E, Marsh K, Williams TN, Kamau T, Sharif SK, Levine OS, Scott JAG. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet 2019;393:2146-54. [PMID: 31000194 DOI: 10.1016/S0140-6736(18)33005-8] [Cited by in Crossref: 56] [Cited by in F6Publishing: 28] [Article Influence: 18.7] [Reference Citation Analysis]
Number Citing Articles
1 Garcia Quesada M, Yang Y, Bennett JC, Hayford K, Zeger SL, Feikin DR, Peterson ME, Cohen AL, Almeida SCG, Ampofo K, Ang M, Bar-Zeev N, Bruce MG, Camilli R, Chanto Chacón G, Ciruela P, Cohen C, Corcoran M, Dagan R, De Wals P, Desmet S, Diawara I, Gierke R, Guevara M, Hammitt LL, Hilty M, Ho PL, Jayasinghe S, Kleynhans J, Kristinsson KG, Ladhani SN, McGeer A, Mwenda JM, Nuorti JP, Oishi K, Ricketson LJ, Sanz JC, Savrasova L, Setchanova LP, Smith A, Valentiner-Branth P, Valenzuela MT, van der Linden M, van Sorge NM, Varon E, Winje BA, Yildirim I, Zintgraff J, Knoll MD, The Pserenade Team. Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project. Microorganisms 2021;9:738. [PMID: 33916227 DOI: 10.3390/microorganisms9040738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Klugman KP, Rodgers GL. Population versus individual protection by pneumococcal conjugate vaccination. Lancet 2019;393:2102-4. [PMID: 31000193 DOI: 10.1016/S0140-6736(19)30039-X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Awori JO, Kamau A, Morpeth S, Kazungu S, Silaba M, Sande J, Karani A, Nyongesa S, Mwarumba S, Musyimi R, Bett A, Wande S, Shebe M, Ngama M, Munywoki PK, Muturi N, Nokes DJ, Feikin DR, Murdoch DR, Prosperi C, O'Brien KL, Deloria Knoll M, Hammitt LL, Scott JAG. The Etiology of Pneumonia in HIV-uninfected Children in Kilifi, Kenya: Findings From the Pneumonia Etiology Research for Child Health (PERCH) Study. Pediatr Infect Dis J 2021;40:S29-39. [PMID: 34448742 DOI: 10.1097/INF.0000000000002653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kaboré L, Adebanjo T, Njanpop-Lafourcade BM, Ouangraoua S, Tarbangdo FT, Meda B, Velusamy S, Bicaba B, Aké F, McGee L, Yaro S, Betsem E, Gervaix A, Gessner BD, Whitney CG, Moïsi JC, Van Beneden CA. Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys. J Infect Dis 2021;224:S258-66. [PMID: 34469552 DOI: 10.1093/infdis/jiab037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Flynn MF, Kelly M, Dooley JSG. Nasopharyngeal Swabs vs. Nasal Aspirates for Respiratory Virus Detection: A Systematic Review. Pathogens 2021;10:1515. [PMID: 34832670 DOI: 10.3390/pathogens10111515] [Reference Citation Analysis]
6 Lewnard JA, Lo NC, Arinaminpathy N, Frost I, Laxminarayan R. Childhood vaccines and antibiotic use in low- and middle-income countries. Nature 2020;581:94-9. [PMID: 32376956 DOI: 10.1038/s41586-020-2238-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
7 Nzoyikorera N, Diawara I, Fresia P, Maaloum F, Katfy K, Nayme K, Maaloum M, Cornick J, Chaguza C, Timinouni M, Belabess H, Zerouali K, Elmdaghri N. Whole genomic comparative analysis of Streptococcus pneumoniae serotype 1 isolates causing invasive and non-invasive infections among children under 5 years in Casablanca, Morocco. BMC Genomics 2021;22:39. [PMID: 33413118 DOI: 10.1186/s12864-020-07316-0] [Reference Citation Analysis]
8 Thindwa D, Pinsent A, Ojal J, Gallagher KE, French N, Flasche S. Vaccine strategies to reduce the burden of pneumococcal disease in HIV-infected adults in Africa. Expert Rev Vaccines 2020;19:1085-92. [PMID: 33269987 DOI: 10.1080/14760584.2020.1843435] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Bentley SD, Lo SW. Global genomic pathogen surveillance to inform vaccine strategies: a decade-long expedition in pneumococcal genomics. Genome Med 2021;13:84. [PMID: 34001237 DOI: 10.1186/s13073-021-00901-2] [Reference Citation Analysis]
10 Nisar MI, Ahmed S, Jehan F, Shahid S, Shakoor S, Kabir F, Hotwani A, Munir S, Muhammad S, Khalid F, Althouse B, Hu H, Whitney C, Ali A, Zaidi AKM, Omer SB, Iqbal N. Direct and indirect effect of 10 valent pneumococcal vaccine on nasopharyngeal carriage in children under 2 years of age in Matiari, Pakistan. Vaccine 2021;39:1319-27. [PMID: 33422379 DOI: 10.1016/j.vaccine.2020.12.066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ngocho JS, Minja L, van der Gaast-de Jongh CE, Rahamat-Langendoen JC, Langereis JD, Mmbaga BT, de Jonge MI. Viral-bacterial (co-)occurrence in the upper airways and the risk of childhood pneumonia in resource-limited settings. J Infect 2020;81:213-20. [PMID: 32533999 DOI: 10.1016/j.jinf.2020.06.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Rodgers GL, Whitney CG, Klugman KP. Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe. J Infect Dis 2021;224:S352-9. [PMID: 34590137 DOI: 10.1093/infdis/jiaa535] [Reference Citation Analysis]
13 Cook HM, Giele CM, Jayasinghe SH, Wakefield A, Krause VL; Enhanced Invasive Pneumococcal Disease Surveillance Working Group. An outbreak of serotype-1 sequence type 306 invasive pneumococcal disease in an Australian Indigenous population. Commun Dis Intell (2018) 2020;44. [PMID: 32988336 DOI: 10.33321/cdi.2020.44.66] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Lourenço J, Obolski U, Swarthout TD, Gori A, Bar-Zeev N, Everett D, Kamng'ona AW, Mwalukomo TS, Mataya AA, Mwansambo C, Banda M, Gupta S, French N, Heyderman RS. Determinants of high residual post-PCV13 pneumococcal vaccine-type carriage in Blantyre, Malawi: a modelling study. BMC Med 2019;17:219. [PMID: 31801542 DOI: 10.1186/s12916-019-1450-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
15 Bennett JC, Hetrich MK, Garcia Quesada M, Sinkevitch JN, Deloria Knoll M, Feikin DR, Zeger SL, Kagucia EW, Cohen AL, Ampofo K, Brandileone MC, Bruden D, Camilli R, Castilla J, Chan G, Cook H, Cornick JE, Dagan R, Dalby T, Danis K, de Miguel S, De Wals P, Desmet S, Georgakopoulou T, Gilkison C, Grgic-Vitek M, Hammitt LL, Hilty M, Ho PL, Jayasinghe S, Kellner JD, Kleynhans J, Knol MJ, Kozakova J, Kristinsson KG, Ladhani SN, MacDonald L, Mackenzie GA, Mad'arová L, McGeer A, Mereckiene J, Morfeldt E, Mungun T, Muñoz-Almagro C, Nuorti JP, Paragi M, Pilishvili T, Puentes R, Saha SK, Sahu Khan A, Savrasova L, Scott JA, Skoczyńska A, Suga S, van der Linden M, Verani JR, von Gottberg A, Winje BA, Yildirim I, Zerouali K, Hayford K, The Pserenade Team. Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 Following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project. Microorganisms 2021;9:696. [PMID: 33801760 DOI: 10.3390/microorganisms9040696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Tvedskov ESF, Hovmand N, Benfield T, Tinggaard M. Pneumococcal carriage among children in low and lower-middle-income countries: A systematic review. Int J Infect Dis 2021;115:1-7. [PMID: 34800691 DOI: 10.1016/j.ijid.2021.11.021] [Reference Citation Analysis]
17 Mackenzie GA, Osei I, Salaudeen R, Hossain I, Young B, Secka O, D'Alessandro U, Palmu AA, Jokinen J, Hinds J, Flasche S, Mulholland K, Nguyen C, Greenwood B. A cluster-randomised, non-inferiority trial of the impact of a two-dose compared to three-dose schedule of pneumococcal conjugate vaccination in rural Gambia: the PVS trial. Trials 2022;23:71. [PMID: 35073989 DOI: 10.1186/s13063-021-05964-5] [Reference Citation Analysis]
18 Swarthout TD, Fronterre C, Lourenço J, Obolski U, Gori A, Bar-Zeev N, Everett D, Kamng'ona AW, Mwalukomo TS, Mataya AA, Mwansambo C, Banda M, Gupta S, Diggle P, French N, Heyderman RS. High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi. Nat Commun 2020;11:2222. [PMID: 32376860 DOI: 10.1038/s41467-020-15786-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
19 Temple B, Nation ML, Dai VTT, Beissbarth J, Bright K, Dunne EM, Hinds J, Hoan PT, Lai J, Nguyen CD, Ortika BD, Phan TV, Thuy HNL, Toan NT, Uyen DY, Satzke C, Smith-Vaughan H, Huu TN, Mulholland K. Effect of a 2+1 schedule of ten-valent versus 13-valent pneumococcal conjugate vaccine on pneumococcal carriage: Results from a randomised controlled trial in Vietnam. Vaccine 2021;39:2303-10. [PMID: 33745731 DOI: 10.1016/j.vaccine.2021.02.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tang L, Ding XY, Duan LF, Li L, Lu HD, Zhou F, Shi L, Lu J, Shen Y, Zhuang ZW, Sun JT, Zhou Q, Zhu CQ, Li JJ, Yu YX. A Regression Model to Predict Augmented Renal Clearance in Critically Ill Obstetric Patients and Effects on Vancomycin Treatment. Front Pharmacol 2021;12:622948. [PMID: 34177564 DOI: 10.3389/fphar.2021.622948] [Reference Citation Analysis]
21 Izurieta P, Nieto Guevara J. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease. Hum Vaccin Immunother 2021;:1-8. [PMID: 33605846 DOI: 10.1080/21645515.2021.1872341] [Reference Citation Analysis]
22 Ojal J, Griffiths U, Hammitt LL, Adetifa I, Akech D, Tabu C, Scott JAG, Flasche S. Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya. Lancet Glob Health 2019;7:e644-54. [PMID: 31000132 DOI: 10.1016/S2214-109X(18)30562-X] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Negash AA, Asrat D, Abebe W, Hailemariam T, Gebre M, Verhaegen J, Aseffa A, Vaneechoutte M. Pneumococcal Carriage, Serotype Distribution, and Risk Factors in Children With Community-Acquired Pneumonia, 5 Years After Introduction of the 10-Valent Pneumococcal Conjugate Vaccine in Ethiopia. Open Forum Infect Dis 2019;6:ofz259. [PMID: 31263735 DOI: 10.1093/ofid/ofz259] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Bar-Zeev N, Swarthout TD, Everett DB, Alaerts M, Msefula J, Brown C, Bilima S, Mallewa J, King C, von Gottberg A, Verani JR, Whitney CG, Mwansambo C, Gordon SB, Cunliffe NA, French N, Heyderman RS; VacSurv Consortium. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control studies. Lancet Glob Health 2021;9:e989-98. [PMID: 34143997 DOI: 10.1016/S2214-109X(21)00165-0] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Chaguza C, Yang M, Jacques LC, Bentley SD, Kadioglu A. Serotype 1 pneumococcus: epidemiology, genomics, and disease mechanisms. Trends in Microbiology 2021. [DOI: 10.1016/j.tim.2021.11.007] [Reference Citation Analysis]
26 Mackenzie GA, Hill PC, Jeffries DJ, Ndiaye M, Sahito SM, Hossain I, Uchendu U, Ameh D, Adeyemi O, Pathirana J, Olatunji Y, Abatan B, Muhammad BS, Ahameefula E, Fombah AE, Adeshola B, Lobga BG, Saha D, Mackenzie R, Odutola A, Plumb ID, Akano A, Ebruke BE, Ideh RC, Kuti B, Githua P, Olutunde E, Ofordile O, Green E, Usuf E, Badji H, Ikumapayi UN, Manjang A, Salaudeen R, Nsekpong ED, Jarju S, Antonio M, Sambou S, Ceesay L, Lowe-Jallow Y, Fofana S, Jasseh M, Mulholland K, Knoll M, Levine OS, Howie SR, Adegbola RA, Greenwood BM, Corrah T; Gambia Pneumococcal Surveillance Group. Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance. Lancet Infect Dis 2021;21:1293-302. [PMID: 34280357 DOI: 10.1016/S1473-3099(20)30880-X] [Reference Citation Analysis]
27 Ozawa S, Chen HH, Rao GG, Eguale T, Stringer A. Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): Case study using DREAMR in Ethiopia. Vaccine 2021;39:6700-11. [PMID: 34538697 DOI: 10.1016/j.vaccine.2021.04.024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Chaguza C, Senghore M, Bojang E, Lo SW, Ebruke C, Gladstone RA, Tientcheu PE, Bancroft RE, Worwui A, Foster-Nyarko E, Ceesay F, Okoi C, McGee L, Klugman KP, Breiman RF, Barer MR, Adegbola RA, Antonio M, Bentley SD, Kwambana-Adams BA. Carriage Dynamics of Pneumococcal Serotypes in Naturally Colonized Infants in a Rural African Setting During the First Year of Life. Front Pediatr 2020;8:587730. [PMID: 33489998 DOI: 10.3389/fped.2020.587730] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Negash AA, Asrat D, Abebe W, Hailemariam T, Hailu T, Aseffa A, Vaneechoutte M. Bacteremic Community-Acquired Pneumonia in Ethiopian Children: Etiology, Antibiotic Resistance, Risk Factors, and Clinical Outcome. Open Forum Infect Dis 2019;6:ofz029. [PMID: 30838226 DOI: 10.1093/ofid/ofz029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
30 Feldman C, Anderson R. Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections. F1000Res 2020;9:F1000 Faculty Rev-338. [PMID: 32411353 DOI: 10.12688/f1000research.22341.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
31 Njuma Libwea J, Fletcher MA, Koki Ndombo P, Boula A, Ashukem NT, Ngo Baleba M, Kingue Bebey RS, Nkolo Mviena EG, Tageube J, Kobela Mbollo M, Koulla-Shiro S, Madhi S, Njanpop-Lafourcade BM, Mohammad A, Begier E, Southern J, Beavon R, Gessner B. Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ˂5 years in Cameroon, 2011-2018. PLoS One 2021;16:e0250010. [PMID: 33857235 DOI: 10.1371/journal.pone.0250010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Pecenka C, Usuf E, Hossain I, Sambou S, Vodicka E, Atherly D, Mackenzie G. Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications. BMJ Glob Health 2021;6:e007211. [PMID: 34916274 DOI: 10.1136/bmjgh-2021-007211] [Reference Citation Analysis]
33 Reyburn R, Tuivaga EJ, Ratu FT, Dunne EM, Nand D, Kado J, Jenkins K, Tikoduadua L, Jenney A, Howden BP, Ballard SA, Fox K, Devi R, Satzke C, Rafai E, Kama M, Flasche S, Mulholland EK, Russell FM. The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji. Lancet Reg Health West Pac 2022;20:100352. [PMID: 35028629 DOI: 10.1016/j.lanwpc.2021.100352] [Reference Citation Analysis]
34 Onwuchekwa C, Edem B, Williams V, Oga E. Estimating the impact of pneumococcal conjugate vaccines on childhood pneumonia in sub-Saharan Africa: A systematic review. F1000Res 2020;9:765. [PMID: 33335713 DOI: 10.12688/f1000research.25227.2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Swarthout TD, Ibarz-Pavon A, Kawalazira G, Sinjani G, Chirombo J, Gori A, Chalusa P, Bonomali F, Nyirenda R, Bulla E, Brown C, Msefula J, Banda M, Kachala J, Mwansambo C, Henrion MY, Gordon SB, French N, Heyderman RS. A pragmatic health centre-based evaluation comparing the effectiveness of a PCV13 schedule change from 3+0 to 2+1 in a high pneumococcal carriage and disease burden setting in Malawi: a study protocol. BMJ Open 2021;11:e050312. [PMID: 34140345 DOI: 10.1136/bmjopen-2021-050312] [Reference Citation Analysis]
36 Murdoch DR. Assessing the Impact of Pneumococcal Conjugate Vaccines. Clin Infect Dis 2020;70:1589-90. [PMID: 31175809 DOI: 10.1093/cid/ciz484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Alderson MR, Sethna V, Newhouse LC, Lamola S, Dhere R. Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL®). Hum Vaccin Immunother 2021;17:2670-7. [PMID: 33625961 DOI: 10.1080/21645515.2021.1874219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Regalado L D, Rivera-Olivero IA, Garcia-Bereguiain MA, Tana L, Hernandez I, Zurita J, Vidal JE, Terán E, de Waard JH. Pneumococcal Carriage Among Indigenous Kichwa Children From the Ecuadorian Andes After the 10-Valent Pneumococcal Vaccine Introduction. Pediatr Infect Dis J 2021;40:e427-33. [PMID: 34609109 DOI: 10.1097/INF.0000000000003291] [Reference Citation Analysis]
39 Kelly MS, Plunkett C, Yu Y, Aquino JN, Patel SM, Hurst JH, Young RR, Smieja M, Steenhoff AP, Arscott-Mills T, Feemster KA, Boiditswe S, Leburu T, Mazhani T, Patel MZ, Rawls JF, Jawahar J, Shah SS, Polage CR, Cunningham CK, Seed PC. Non-diphtheriae Corynebacterium species are associated with decreased risk of pneumococcal colonization during infancy. ISME J 2021. [PMID: 34511605 DOI: 10.1038/s41396-021-01108-4] [Reference Citation Analysis]